Table 1.
Characteristics of Individuals Who Received 2 Doses of Recombinant Zoster Vaccine With and Without Concomitant Vaccine
| Characteristic | RZV With Concomitant Vaccinea | RZV Without Concomitant Vaccine | Total (N = 41 251) | P Value |
|---|---|---|---|---|
| (n = 12 898) | (n = 28 353) | |||
| Age at index dateb | <.001 | |||
| 50–59 y | 2134 (16.5) | 3782 (13.3) | 5916 (14.3) | |
| 60–69 y | 5676 (44.0) | 9528 (33.6) | 15 204 (36.9) | |
| 70–79 y | 3920 (30.4) | 11 043 (38.9) | 14 963 (36.3) | |
| ≥80 y | 1168 (9.1) | 4000 (14.1) | 5168 (12.5) | |
| Sex | <.001 | |||
| Female | 7359 (57.1) | 16 767 (59.1) | 24 126 (58.5) | |
| Male | 5539 (42.9) | 11 586 (40.9) | 17 125 (41.5) | |
| Race/Ethnicity | <.001 | |||
| Non-Hispanic White | 7788 (60.4) | 17 279 (60.9) | 25 067 (60.8) | |
| Non-Hispanic Black | 498 (3.9) | 1109 (3.9) | 1607 (3.9) | |
| Hispanic | 2171 (16.8) | 4194 (14.8) | 6365 (15.4) | |
| Non-Hispanic Asian | 1991 (15.4) | 4909 (17.3) | 6900 (16.7) | |
| Otherc | 450 (3.5) | 862 (3.0) | 1312 (3.2) | |
| Receipt of ZVLd | <.001 | |||
| ≤5 y ago | 1086 (8.4) | 2291 (8.1) | 3377 (8.2) | |
| >5 y ago | 4956 (38.4) | 13 479 (47.5) | 18 435 (44.7) | |
| No ZVL | 6856 (53.2) | 12 583 (44.4) | 19 439 (47.1) | |
| History of HZd | 1420 (11.0) | 3401 (12.0) | 4821 (11.7) | .004 |
| Season/year of index date | <.001 | |||
| Apr 2018–Aug 2018 | 587 (4.6) | 2087 (7.4) | 2674 (6.5) | |
| Sep 2018–Mar 2019 | 5573 (43.2) | 9397 (33.1) | 14 970 (36.3) | |
| Apr 2019–Sep 2019 | 6738 (52.2) | 16 869 (59.5) | 23 607 (57.2) | |
| Immunocompromisede | 557 (4.3) | 1320 (4.7) | 1877 (4.6) | .128 |
| Comorbiditiesf | ||||
| Kidney disease | 1453 (11.3) | 3752 (13.2) | 5205 (12.6) | <.001 |
| Heart disease | 606 (4.7) | 1770 (6.2) | 2376 (5.8) | <.001 |
| Lung disease | 1818 (14.1) | 4446 (15.7) | 6264 (15.2) | <.001 |
| Liver disease | 492 (3.8) | 1188 (4.2) | 1680 (4.1) | .074 |
| Diabetes | 2681 (20.8) | 5857 (20.7) | 8538 (20.7) | .765 |
| No. of hospitalizationsf | <.001 | |||
| 0 | 12 334 (95.6) | 26 871 (94.8) | 39 205 (95.0) | |
| 1 | 464 (3.6) | 1166 (4.1) | 1630 (4.0) | |
| ≥2 | 100 (0.8) | 316 (1.1) | 416 (1.0) | |
| No. of ED visitsf | <.001 | |||
| 0 | 10 988 (85.2) | 23 603 (83.2) | 34 591 (83.9) | |
| 1 | 1388 (10.8) | 3329 (11.7) | 4717 (11.4) | |
| ≥2 | 522 (4.0) | 1421 (5.0) | 1943 (4.7) | |
| No. of outpatient visitsf | <.001 | |||
| 0–4 | 3008 (23.3) | 4249 (15.0) | 7257 (17.6) | |
| 5–10 | 4777 (37.0) | 9902 (34.9) | 14 679 (35.6) | |
| ≥11 | 5113 (39.6) | 14 202 (50.1) | 19 315 (46.8) | |
| No. of virtual contactsf,g | <.001 | |||
| 0–10 | 10 763 (83.4) | 22 647 (79.9) | 33 410 (81.0) | |
| 11–20 | 1507 (11.7) | 3843 (13.6) | 5350 (13.0) | |
| ≥21 | 628 (4.9) | 1863 (6.6) | 2491 (6.0) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ED, emergency department; HZ, herpes zoster; RZV, recombinant zoster vaccine; ZVL, zoster vaccine live.
Defined as another vaccine received on the same day as either the first or second RZV dose.
The index date was the date of the second RZV dose.
Includes other, multiple, or unknown race/ethnicity.
Defined in any year prior to index date.
Defined as human immunodeficiency virus, leukemia, lymphoma, congenital immunodeficiencies, asplenia/hyposplenia, and transplant (including heart, kidney, liver, lung, pancreas, and bone marrow) prior to index date, or receipt of nonsteroidal immunosuppressing medications overlapping with index date.
Defined in 1 year prior to index date.
Virtual contacts included email, e-visit, telephone appointment visit, and video.